Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract CancerDo‐Youn Oh, Juan W. Valle, Thatthan Suksombooncharoen et al.|NEJM Evidence|2022Cited by 1.1k
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 studyDo‐Youn Oh, Juan W. Valle, Aiwu Ruth He et al.|The Lancet. Gastroenterology & hepatology|2024Cited by 245
Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline)In‐Ho Kim, Seung Joo Kang, Wonyoung Choi et al.|Journal of the Korean Gastric Cancer Association|2025Cited by 96
A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancerChoong‐kun Lee, Hyun Cheol Chung|Nature Communications|2022Cited by 53